- Home
- » Tags
- » Panitumumab
Top View
- Cetuximab and Panitumumab for Previously Untreated Metastatic Colorectal Cancer
- CDER List of Licensed Biological Products With
- Clinical Potential of Necitumumab in Non-Small Cell Lung Carcinoma
- Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer Funda Meric-Bernstam1,2,3, Amber M
- Spotlight on Necitumumab in the Treatment of Non-Small-Cell Lung Carcinoma
- 099 Quality Care Cancer Program (Medical Oncology)
- Assessment Report
- Vectibix (Panitumumab) Is a Recombinant, Human Igg2 Kappa Monoclonal Antibody That Binds Specifically to the Human Epidermal Growth Factor Receptor (EGFR)
- DAIICHI SANKYO CO., LTD. Sunao Manabe President and CEO June 8, 2021
- Specialty Injectables Prior Authorization List
- Chemotherapy: Drugs P-Z Policy (Chemo Drug P-Z)
- “What's New” Medical Pharmaceutical Policy Updates March
- Candidate Biomarkers for Specific Intraoperative Near-Infrared
- Table 1. Summary of Kinase Inhibitors Approved by the FDA for Treatment
- Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance Atrish Bagchi1,2, Jaafar N
- Oncology Medications Policy (1403)
- Co-Treatment with Panitumumab and Trastuzumab Augments Response
- U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer